Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| CEL SCI Corp.CVM · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $28.2M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | dilution, late filer, thin datanot computable: short runway, distress, fortress balance sheet |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Dec 29, 2025284 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $2.032026-10-08; market equity $35.7M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Dec 29, 2025; the document on sec.gov.
CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 14.4 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (30.1%) | [1,5-7] | (6.6%) | 14.4 | 811 | 2025-09-30 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 80.0 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (65.50) | [1,8-13] | (0.31) | 91.1 | 756 | 2025-09-30 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| required facts have no common fiscal period end | |||||||
| Interest coverage | (38.23x) | [11,14] | (4.51x) | 81.2 | 81 | 2025-09-30 | |
| Current ratio | 2.26x | [8-9] | 2.96x | 67.5 | 839 | 2025-09-30 | |
| Growth and financing, sleeve percentile 85.3 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 3 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (17.7%) | [1,7,15-16] | 2.1% | 79.8 | 704 | 2025-09-30 | |
| Net share issuance, one year | 240.3% | [3-4] | 2.5% | 90.8 | 634 | 2025-12-19 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (82.4%) | 8.0% | 4 | hotter than 4 of 100 peers |
| Distance from 52-week high | (80.7%) | (31.4%) | 8 | closer to its high than 8 of 100 peers |
| EBIT to enterprise value | (71.2%) | (1.5%) | 10 | pricier than 90 of 100 peers |
| Free cash flow yield | (50.0%) | (1.0%) | 12 | pricier than 88 of 100 peers |
| Book value to price | 0.32 | 0.28 | 53 | pricier than 47 of 100 peers |
| Sales to price | 0.01 | 0.31 | 6 | pricier than 94 of 100 peers |
| Composite equity issuance, five years | 258.6% | 20.3% | 94 | more equity-funded than 94 of 100 peers |
| Relative strength against the sector, log excess return | (1.95) | (0.14) | 4 | ahead of 4 of 100 peers |
Inputs: market equity $34.3M; EBIT -$24.8M; free cash flow -$17.2M; book equity $11.0M; sales $264,033; debt $5.7M; cash $5.1M[17].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-09-30 | ||
|---|---|---|
| Return on assets above zero | (94.1%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$17.1M | ✗ fail[6] |
| Return on assets improved | (6.0 pts) | ✗ fail[5,7,15,18] |
| Operating cash flow exceeds net income | $8.3M | ✓ pass[5-6] |
| Long-term leverage fell | n/a[1,7,15,19] | |
| Current ratio improved | 94.8 pts | ✓ pass[8-9,20-21] |
| No new shares issued | 240.3% | ✗ fail[3-4] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[7,15] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a[6,22-25] |
| Months of runway | not finite |
| cash is missing at the end of the latest cash-flow quarter | |
| Late filings, two years | 1 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 56 |
| 10-Q received Aug 14, 2026 | |
| Median daily dollar volume | $226,274 |
| 63 sessions | |
| Days since newest grade input | 284 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $28.2M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $264,033 | 2014-09-30 | 2014-12-23 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 8,408,746 | 2025-12-19 | 2025-12-29 | 10-K | filing · viewer · series |
| 4 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 74,107,041 | 2025-01-06 | 2025-01-13 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$25.4M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$17.1M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $27.0M | 2024-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 8 | current assets | us-gaap:AssetsCurrent | $11.6M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $5.1M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$539.4M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$24.8M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $16.0M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 13 | liabilities | us-gaap:Liabilities | $12.2M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 14 | interest expense | us-gaap:InterestExpense | $649,000 | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $30.5M | 2023-09-30 | 2025-01-13 | 10-K | filing · viewer · series |
| 16 | assets | us-gaap:Assets | $50.5M | 2022-09-30 | 2023-12-21 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 17,588,987 | 2026-08-10 | 2026-08-14 | 10-Q | filing · viewer · series |
| 18 | net income | us-gaap:NetIncomeLoss | -$26.9M | 2024-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 19 | long term debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $5.7M | 2025-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 20 | current assets | us-gaap:AssetsCurrent | $6.1M | 2024-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 21 | current liabilities | us-gaap:LiabilitiesCurrent | $4.6M | 2024-09-30 | 2025-12-29 | 10-K | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.1M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.0M | 2026-03-31 | 2026-05-15 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$4.0M | 2025-12-31 | 2026-02-17 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.4M | 2025-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.